Kan He

List of Publications by Year
in descending order

23 papers	635 citations	759233 12 h-index	888059 17 g-index
24 all docs	24 docs citations	24 times ranked	1012 citing authors

#	Article	IF	Citations
1	Berberine inhibits chemotherapy-exacerbated ovarian cancer stem cell-like characteristics and metastasis through GLI1. European Journal of Pharmacology, 2021, 895, 173887.	3.5	9
2	Biomimetic co-assembled nanodrug of doxorubicin and berberine suppresses chemotherapy-exacerbated breast cancer metastasis. Biomaterials, 2021, 271, 120716.	11.4	49
3	Analysis of Serum Metabolomics in Rats with Osteoarthritis by Mass Spectrometry. Molecules, 2021, 26, 7181.	3.8	8
4	HNF-4Î± inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway. PLoS ONE, 2020, 15, e0230450.	2.5	20
5	Chemotherapy exacerbates ovarian cancer cell migration and cancer stem cell-like characteristics through GLI1. British Journal of Cancer, 2020, 122, 1638-1648.	6.4	21
6	Berberine Inhibits the Apoptosis-Induced Metastasis by Suppressing the iPLA2/LOX-5/LTB4 Pathway in Hepatocellular Carcinoma . OncoTargets and Therapy, 2020, Volume 13, 5223-5230.	2.0	9
7	HNF-4Î± inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway. , 2020, 15, e0230450.		0
8	HNF-4Î± inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway. , 2020, 15, e0230450.		0
9	HNF-4Î± inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway. , 2020, 15, e0230450.		0
10	HNF-4Î± inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway. , 2020, 15, e0230450.		0
11	HNF-4Î± inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway. , 2020, 15, e0230450.		0
12	HNF-4Î± inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway. , 2020, 15, e0230450.		0
13	5-FU preferably induces apoptosis in BRAF V600E colorectal cancer cells via downregulation of Bcl-xL. Molecular and Cellular Biochemistry, 2019, 461, 151-158.	3.1	4
14	Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence. Acta Biomaterialia, 2019, 100, 352-364.	8.3	44
15	Depression promotes hepatocellular carcinoma progression through a glucocorticoid-mediated upregulation of PD-1 expression in tumor-infiltrating NK cells. Carcinogenesis, 2019, , .	2.8	17
16	Berberine-based carbon dots for selective and safe cancer theranostics. RSC Advances, 2018, 8, 1168-1173.	3.6	29
17	Shape-controlled magnetic mesoporous silica nanoparticles for magnetically-mediated suicide gene therapy of hepatocellular carcinoma. Biomaterials, 2018, 154, 147-157.	11.4	127
18	Obesity-associated miR-27a upregulation promotes hepatocellular carcinoma metastasis through suppressing SFRP1. OncoTargets and Therapy, 2018, Volume 11, 3281-3292.	2.0	10

#	Article	IF	Citations
19	Self-assembled dual fluorescence nanoparticles for CD44-targeted delivery of anti-miR-27a in liver cancer theranostics. Theranostics, 2018, 8, 3808-3823.	10.0	41
20	Berberine inhibits the chemotherapyâ€induced repopulation by suppressing the arachidonic acid metabolic pathway and phosphorylation of <scp>FAK</scp> in ovarian cancer. Cell Proliferation, 2017, 50, .	5.3	48
21	Chemotherapy induces ovarian cancer cell repopulation through the caspase 3-mediated arachidonic acid metabolic pathway. OncoTargets and Therapy, 2017, Volume 10, 5817-5826.	2.0	20
22	Berberine Reverses Hypoxia-induced Chemoresistance in Breast Cancer through the Inhibition of AMPK- HIF-1Î±. International Journal of Biological Sciences, 2017, 13, 794-803.	6.4	81
23	Berberine Enhances Chemosensitivity and Induces Apoptosis Through Dose-orchestrated AMPK Signaling in Breast Cancer. Journal of Cancer, 2017, 8, 1679-1689.	2.5	98